Candel Plans to Submit New Drug Application
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 16 2026
0mins
Source: stocktwits
- Clinical Trial Results: Candel Therapeutics reported that after a median follow-up of 58 months, CAN-2409 demonstrated a 39% improvement in prostate cancer-specific disease-free survival compared to placebo in its pivotal late-stage trial, highlighting the drug's potential in prostate cancer treatment.
- Subgroup Analysis Advantage: In the intermediate-risk subgroup, which comprised 85% of the 745 patients, CAN-2409 achieved a 41% reduction in recurrence risk, along with significant improvements in time to biochemical failure, time to metastasis, and time to next anti-cancer therapy, further solidifying its clinical value.
- FDA Application Plans: Candel intends to submit a Biologics License Application to the FDA in Q4 2026, and if approved, CAN-2409 would be the first new therapy added to standard radiotherapy for localized prostate cancer in over 20 years, marking a significant market opportunity.
- Positive Market Reaction: Following the release of extended follow-up data, Candel's shares rose 3% in after-hours trading, and the stock has increased by 72% over the past 12 months, reflecting strong investor confidence in the drug's prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CADL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CADL
Wall Street analysts forecast CADL stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 9.880
Low
7.00
Averages
18.33
High
25.00
Current: 9.880
Low
7.00
Averages
18.33
High
25.00
About CADL
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Candel Launches Global Phase 3 Clinical Trial for Cancer Therapy
- Global Recruitment Initiative: Candel Therapeutics has launched its Phase 3 Aurora clinical trial across more than 150 sites worldwide, aiming to evaluate its cancer therapy Aglatimagene Besadenovec (CAN-2409) in non-small cell lung cancer patients, reflecting the company's ambition to expand its clinical footprint in oncology.
- Positive Clinical Data: Recent data published in Lancet Oncology indicates that CAN-2409 achieved a 30% improvement in disease-free survival in localized prostate cancer during Phase 3 trials, supporting Candel's plans to submit a Biologics License Application in Q4 2026, thereby bolstering market confidence in its product pipeline.
- Strong Financial Position: Candel reported cash and cash equivalents totaling $194.8 million, which are expected to fund operations into Q1 2028, ensuring continued investment in clinical trials and market development.
- Positive Market Reaction: Candel's shares surged 9% on Tuesday, reaching a 16-month high, with retail sentiment shifting to 'extremely bullish', indicating strong investor confidence in the company's future prospects.
See More
Investors Must Maintain Emotional Neutrality
- Investor Mindset: Robert Kiyosaki emphasizes that successful business owners and investors must maintain emotional neutrality towards winning and losing, viewing these as mere parts of the game, which helps in staying rational and patient in volatile markets.
- Twist Bioscience Performance: Twist Bioscience reported strong revenue performance for fiscal year 2025 and the first half of fiscal 2026, with third-quarter revenue expected to reach approximately $114 million to $115 million, reflecting a year-over-year growth of about 19%, showcasing its sustained growth potential in synthetic biology.
- Biodesix Clinical Validation: Biodesix's Nodify CDT test demonstrated strong performance in the largest clinical validation study for lung nodule biomarkers, with financial results for Q2 2026 expected to further boost stock prices, highlighting its leading position in early lung cancer diagnosis.
- Mirum Pharmaceuticals Progress: Mirum Pharmaceuticals' strong Q1 2026 results and the anticipated FDA decision on Zilurgisertib indicate its innovative capabilities in rare disease treatments and market confidence, which are expected to drive future stock performance.
See More
Candel's Phase 3 Prostate Cancer Therapy Data Released
- Promising Phase 3 Data: Candel Therapeutics published Phase 3 data for its prostate cancer therapy Aglatimagene Besadenovec, showing a 30% improvement in disease-free survival when combined with standard radiotherapy, indicating significant efficacy that is expected to support the upcoming Biologics License Application.
- Patient Enrollment Success: The randomized trial enrolled 745 patients and met its primary endpoint with a 38% improvement in prostate cancer-specific disease-free survival, not only validating the therapy's effectiveness but also establishing a strong foundation for the company's position in the competitive biopharmaceutical market.
- Positive Market Reaction: Candel's stock saw a pre-market boost on Friday as investors remained upbeat about the Phase 3 trial results, putting the stock on track for its best week in a month, reflecting market confidence in the company's future growth potential.
- Optimistic Analyst Ratings: According to Koyfin data, Candel's stock has an average 12-month price target of $19.63, representing a potential upside of around 111%, and carries a Strong Buy consensus rating, indicating high recognition of its prospects among analysts.
See More
Candel Therapeutics Reports Positive Phase 3 Results for Prostate Cancer Treatment
- Clinical Trial Results: Candel Therapeutics announced significant progress in treating high-risk localized prostate cancer, with a 30% improvement in disease-free survival (DFS) reported in 745 patients, as published in The Lancet Oncology, indicating the therapy's potential to enhance patient outcomes.
- Survival Rate Improvement: The combination of Aglatimagene with standard radiotherapy and Valacyclovir resulted in a 38% increase in prostate cancer-specific DFS compared to placebo, with a follow-up period revealing a 39% rate, demonstrating the drug's long-term efficacy.
- Biomarker Analysis: A post-hoc blinded review conducted two years post-radiotherapy showed that 80% of patients treated with Aglatimagene had negative biopsy results, compared to 63% in the placebo group, further validating the therapy's effectiveness and safety profile.
- Safety Profile: Aglatimagene exhibited a generally favorable safety profile, and its use in conjunction with existing treatment options may provide new therapeutic avenues for high-risk prostate cancer patients, enhancing Candel Therapeutics' competitive position in the biopharmaceutical sector.
See More
Candel Plans to Submit New Drug Application
- Clinical Trial Results: Candel Therapeutics reported that after a median follow-up of 58 months, CAN-2409 demonstrated a 39% improvement in prostate cancer-specific disease-free survival compared to placebo in its pivotal late-stage trial, highlighting the drug's potential in prostate cancer treatment.
- Subgroup Analysis Advantage: In the intermediate-risk subgroup, which comprised 85% of the 745 patients, CAN-2409 achieved a 41% reduction in recurrence risk, along with significant improvements in time to biochemical failure, time to metastasis, and time to next anti-cancer therapy, further solidifying its clinical value.
- FDA Application Plans: Candel intends to submit a Biologics License Application to the FDA in Q4 2026, and if approved, CAN-2409 would be the first new therapy added to standard radiotherapy for localized prostate cancer in over 20 years, marking a significant market opportunity.
- Positive Market Reaction: Following the release of extended follow-up data, Candel's shares rose 3% in after-hours trading, and the stock has increased by 72% over the past 12 months, reflecting strong investor confidence in the drug's prospects.
See More
Candel Plans to Submit Biologics License Application
- Clinical Trial Success: Candel's Phase 3 trial met its primary endpoint, demonstrating that 745 patients receiving the therapy had longer disease-free survival compared to those on standard care, indicating the efficacy of its prostate cancer treatment and potentially accelerating FDA approval.
- Biologics License Application Plan: The company plans to submit a Biologics License Application (BLA) to the U.S. FDA by Q4 2026, marking a critical step towards market entry for its prostate cancer therapy, which is expected to significantly enhance its position in the biopharmaceutical sector.
- Positive Market Reaction: Candel's shares rose 3% in pre-market trading on Friday, reflecting investor optimism ahead of pivotal data presentation at the American Urological Association Annual Meeting, particularly regarding follow-up data that has garnered market attention.
- Improved Financial Performance: Candel reported a Q1 loss of $0.14 per share, better than the expected loss of $0.33, indicating improvements in financial management and operational efficiency, which may boost investor confidence and drive further stock price increases.
See More
Candel Launches Global Phase 3 Clinical Trial for Cancer Therapy
- Global Recruitment Initiative: Candel Therapeutics has launched its Phase 3 Aurora clinical trial across more than 150 sites worldwide, aiming to evaluate its cancer therapy Aglatimagene Besadenovec (CAN-2409) in non-small cell lung cancer patients, reflecting the company's ambition to expand its clinical footprint in oncology.
- Positive Clinical Data: Recent data published in Lancet Oncology indicates that CAN-2409 achieved a 30% improvement in disease-free survival in localized prostate cancer during Phase 3 trials, supporting Candel's plans to submit a Biologics License Application in Q4 2026, thereby bolstering market confidence in its product pipeline.
- Strong Financial Position: Candel reported cash and cash equivalents totaling $194.8 million, which are expected to fund operations into Q1 2028, ensuring continued investment in clinical trials and market development.
- Positive Market Reaction: Candel's shares surged 9% on Tuesday, reaching a 16-month high, with retail sentiment shifting to 'extremely bullish', indicating strong investor confidence in the company's future prospects.
See More
Investors Must Maintain Emotional Neutrality
- Investor Mindset: Robert Kiyosaki emphasizes that successful business owners and investors must maintain emotional neutrality towards winning and losing, viewing these as mere parts of the game, which helps in staying rational and patient in volatile markets.
- Twist Bioscience Performance: Twist Bioscience reported strong revenue performance for fiscal year 2025 and the first half of fiscal 2026, with third-quarter revenue expected to reach approximately $114 million to $115 million, reflecting a year-over-year growth of about 19%, showcasing its sustained growth potential in synthetic biology.
- Biodesix Clinical Validation: Biodesix's Nodify CDT test demonstrated strong performance in the largest clinical validation study for lung nodule biomarkers, with financial results for Q2 2026 expected to further boost stock prices, highlighting its leading position in early lung cancer diagnosis.
- Mirum Pharmaceuticals Progress: Mirum Pharmaceuticals' strong Q1 2026 results and the anticipated FDA decision on Zilurgisertib indicate its innovative capabilities in rare disease treatments and market confidence, which are expected to drive future stock performance.
See More
Candel's Phase 3 Prostate Cancer Therapy Data Released
- Promising Phase 3 Data: Candel Therapeutics published Phase 3 data for its prostate cancer therapy Aglatimagene Besadenovec, showing a 30% improvement in disease-free survival when combined with standard radiotherapy, indicating significant efficacy that is expected to support the upcoming Biologics License Application.
- Patient Enrollment Success: The randomized trial enrolled 745 patients and met its primary endpoint with a 38% improvement in prostate cancer-specific disease-free survival, not only validating the therapy's effectiveness but also establishing a strong foundation for the company's position in the competitive biopharmaceutical market.
- Positive Market Reaction: Candel's stock saw a pre-market boost on Friday as investors remained upbeat about the Phase 3 trial results, putting the stock on track for its best week in a month, reflecting market confidence in the company's future growth potential.
- Optimistic Analyst Ratings: According to Koyfin data, Candel's stock has an average 12-month price target of $19.63, representing a potential upside of around 111%, and carries a Strong Buy consensus rating, indicating high recognition of its prospects among analysts.
See More
Candel Therapeutics Reports Positive Phase 3 Results for Prostate Cancer Treatment
- Clinical Trial Results: Candel Therapeutics announced significant progress in treating high-risk localized prostate cancer, with a 30% improvement in disease-free survival (DFS) reported in 745 patients, as published in The Lancet Oncology, indicating the therapy's potential to enhance patient outcomes.
- Survival Rate Improvement: The combination of Aglatimagene with standard radiotherapy and Valacyclovir resulted in a 38% increase in prostate cancer-specific DFS compared to placebo, with a follow-up period revealing a 39% rate, demonstrating the drug's long-term efficacy.
- Biomarker Analysis: A post-hoc blinded review conducted two years post-radiotherapy showed that 80% of patients treated with Aglatimagene had negative biopsy results, compared to 63% in the placebo group, further validating the therapy's effectiveness and safety profile.
- Safety Profile: Aglatimagene exhibited a generally favorable safety profile, and its use in conjunction with existing treatment options may provide new therapeutic avenues for high-risk prostate cancer patients, enhancing Candel Therapeutics' competitive position in the biopharmaceutical sector.
See More
Candel Plans to Submit New Drug Application
- Clinical Trial Results: Candel Therapeutics reported that after a median follow-up of 58 months, CAN-2409 demonstrated a 39% improvement in prostate cancer-specific disease-free survival compared to placebo in its pivotal late-stage trial, highlighting the drug's potential in prostate cancer treatment.
- Subgroup Analysis Advantage: In the intermediate-risk subgroup, which comprised 85% of the 745 patients, CAN-2409 achieved a 41% reduction in recurrence risk, along with significant improvements in time to biochemical failure, time to metastasis, and time to next anti-cancer therapy, further solidifying its clinical value.
- FDA Application Plans: Candel intends to submit a Biologics License Application to the FDA in Q4 2026, and if approved, CAN-2409 would be the first new therapy added to standard radiotherapy for localized prostate cancer in over 20 years, marking a significant market opportunity.
- Positive Market Reaction: Following the release of extended follow-up data, Candel's shares rose 3% in after-hours trading, and the stock has increased by 72% over the past 12 months, reflecting strong investor confidence in the drug's prospects.
See More
Candel Plans to Submit Biologics License Application
- Clinical Trial Success: Candel's Phase 3 trial met its primary endpoint, demonstrating that 745 patients receiving the therapy had longer disease-free survival compared to those on standard care, indicating the efficacy of its prostate cancer treatment and potentially accelerating FDA approval.
- Biologics License Application Plan: The company plans to submit a Biologics License Application (BLA) to the U.S. FDA by Q4 2026, marking a critical step towards market entry for its prostate cancer therapy, which is expected to significantly enhance its position in the biopharmaceutical sector.
- Positive Market Reaction: Candel's shares rose 3% in pre-market trading on Friday, reflecting investor optimism ahead of pivotal data presentation at the American Urological Association Annual Meeting, particularly regarding follow-up data that has garnered market attention.
- Improved Financial Performance: Candel reported a Q1 loss of $0.14 per share, better than the expected loss of $0.33, indicating improvements in financial management and operational efficiency, which may boost investor confidence and drive further stock price increases.
See More
